These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 31293091

  • 21. Risk of Malignancy and Risk of Neoplasia in the Bethesda Indeterminate Categories: Study on 4,532 Thyroid Fine-Needle Aspirations from a Single Institution in India.
    Mahajan S, Srinivasan R, Rajwanshi A, Radotra B, Panda N, Dey P, Gupta N, Nijhawan R.
    Acta Cytol; 2017; 61(2):103-110. PubMed ID: 28407624
    [Abstract] [Full Text] [Related]

  • 22. Molecular alterations in Hürthle cell nodules and preoperative cancer risk.
    Doerfler WR, Nikitski AV, Morariu EM, Ohori NP, Chiosea SI, Landau MS, Nikiforova MN, Nikiforov YE, Yip L, Manroa P.
    Endocr Relat Cancer; 2021 Apr 27; 28(5):301-309. PubMed ID: 33792557
    [Abstract] [Full Text] [Related]

  • 23. Impact of molecular testing on detecting mimics of oncocytic neoplasms in thyroid fine-needle aspirates diagnosed as follicular neoplasm of Hürthle cell (oncocytic) type.
    Landau MS, Nikiforov YE, Ohori NP, Chiosea SI.
    Cancer Cytopathol; 2021 Oct 27; 129(10):788-797. PubMed ID: 33901345
    [Abstract] [Full Text] [Related]

  • 24. Hürthle cell neoplasms diagnosed by fine needle aspiration are not associated with an increased risk of malignancy.
    McKee S, Wu H, Wang X, Cramer H, Lin J, Chen S.
    Acta Cytol; 2014 Oct 27; 58(3):235-8. PubMed ID: 24819535
    [Abstract] [Full Text] [Related]

  • 25. Impact of specific patterns on the sensitivity for follicular and Hurthle cell carcinoma in thyroid fine-needle aspiration.
    Renshaw AA, Gould EW.
    Cancer Cytopathol; 2016 Oct 27; 124(10):729-736. PubMed ID: 27322887
    [Abstract] [Full Text] [Related]

  • 26. Implementing noninvasive follicular thyroid neoplasm with papillary-like nuclear features may potentially impact the risk of malignancy for thyroid nodules categorized as AUS/FLUS and FN/SFN.
    Li W, Sciallis A, Lew M, Pang J, Jing X.
    Diagn Cytopathol; 2018 Feb 27; 46(2):148-153. PubMed ID: 29193839
    [Abstract] [Full Text] [Related]

  • 27. Diagnostic performance of molecular testing in indeterminate (Bethesda III and IV) thyroid nodules with Hürthle cell cytology.
    Raghunathan R, Longstaff XR, Hughes EG, Li SJ, Sant VR, Tseng CH, Rao J, Wu JX, Yeh MW, Livhits MJ.
    Surgery; 2024 Jan 27; 175(1):221-227. PubMed ID: 37926582
    [Abstract] [Full Text] [Related]

  • 28. Preoperative diagnostic categories of fine needle aspiration cytology for histologically proven thyroid follicular adenoma and carcinoma, and Hurthle cell adenoma and carcinoma: Analysis of cause of under- or misdiagnoses.
    Na HY, Moon JH, Choi JY, Yu HW, Jeong WJ, Kim YK, Choe JY, Park SY.
    PLoS One; 2020 Jan 27; 15(11):e0241597. PubMed ID: 33147258
    [Abstract] [Full Text] [Related]

  • 29. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
    Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, Figge JJ, Mandel S, Haugen BR, Burman KD, Baloch ZW, Lloyd RV, Seethala RR, Gooding WE, Chiosea SI, Gomes-Lima C, Ferris RL, Folek JM, Khawaja RA, Kundra P, Loh KS, Marshall CB, Mayson S, McCoy KL, Nga ME, Ngiam KY, Nikiforova MN, Poehls JL, Ringel MD, Yang H, Yip L, Nikiforov YE.
    JAMA Oncol; 2019 Feb 01; 5(2):204-212. PubMed ID: 30419129
    [Abstract] [Full Text] [Related]

  • 30. Diagnostic value of a cytomorphological subclassification of follicular patterned thyroid lesions: a study of 927 consecutive cases with histological correlation.
    Deandrea M, Ragazzoni F, Motta M, Torchio B, Mormile A, Garino F, Magliona G, Gamarra E, Ramunni MJ, Garberoglio R, Limone PP.
    Thyroid; 2010 Oct 01; 20(10):1077-83. PubMed ID: 20883171
    [Abstract] [Full Text] [Related]

  • 31. Thyroid Ultrasound-Guided Fine-Needle Aspiration Cytology Results: Observed Increase in Indeterminate Rate over the Past Decade.
    Manning AM, Yang H, Falciglia M, Mark JR, Steward DL.
    Otolaryngol Head Neck Surg; 2017 Apr 01; 156(4):611-615. PubMed ID: 28118554
    [Abstract] [Full Text] [Related]

  • 32. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
    Nikiforova MN, Mercurio S, Wald AI, Barbi de Moura M, Callenberg K, Santana-Santos L, Gooding WE, Yip L, Ferris RL, Nikiforov YE.
    Cancer; 2018 Apr 15; 124(8):1682-1690. PubMed ID: 29345728
    [Abstract] [Full Text] [Related]

  • 33. The role of ThyroSeq V3 testing in the management of patients with indeterminate thyroid nodules on fine needle aspiration.
    Selvaggi SM.
    Diagn Cytopathol; 2021 Jul 15; 49(7):838-841. PubMed ID: 33864719
    [Abstract] [Full Text] [Related]

  • 34. Copy number variations identified in thyroid FNA specimens are associated with Hürthle cell cytomorphology.
    Abi-Raad R, Prasad ML, Adeniran AJ, Cai G.
    Cancer Cytopathol; 2022 Jun 15; 130(6):415-422. PubMed ID: 35332982
    [Abstract] [Full Text] [Related]

  • 35. Suggesting the cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A retrospective analysis of atypical and suspicious nodules.
    Strickland KC, Howitt BE, Barletta JA, Cibas ES, Krane JF.
    Cancer Cytopathol; 2018 Feb 15; 126(2):86-93. PubMed ID: 28914983
    [Abstract] [Full Text] [Related]

  • 36. Molecular-derived estimation of risk of malignancy for indeterminate thyroid cytology diagnoses.
    Ohori NP, Landau MS, Manroa P, Schoedel KE, Seethala RR.
    J Am Soc Cytopathol; 2020 Feb 15; 9(4):213-220. PubMed ID: 32336670
    [Abstract] [Full Text] [Related]

  • 37. Probability of malignancy as determined by ThyroSeq v3 genomic classifier varies according to the subtype of atypia.
    Gajzer DC, Tjendra Y, Kerr DA, Algashaamy K, Zuo Y, Menendez SG, Jorda M, Garcia-Buitrago M, Gomez-Fernandez C, Velez Torres JM.
    Cancer Cytopathol; 2022 Nov 15; 130(11):881-890. PubMed ID: 35775861
    [Abstract] [Full Text] [Related]

  • 38. A retrospective analysis of molecular testing in cytologically indeterminate thyroid nodules with histologic correlation: Experience at a heterogenous multihospital system.
    Sura GH, Thrall MJ, Rogers J, Hodjat P, Christensen P, Cubb TD, Khadra HS, Thomas JS, Jacobi EM.
    Diagn Cytopathol; 2024 Feb 15; 52(2):82-92. PubMed ID: 37950548
    [Abstract] [Full Text] [Related]

  • 39. The impact of atypia/follicular lesion of undetermined significance on the rate of malignancy in thyroid fine-needle aspiration: evaluation of the Bethesda System for Reporting Thyroid Cytopathology.
    Broome JT, Solorzano CC.
    Surgery; 2011 Dec 15; 150(6):1234-41. PubMed ID: 22136846
    [Abstract] [Full Text] [Related]

  • 40. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes.
    Mai KT, Bokhary R, Yazdi HM, Thomas J, Commons AS.
    Histopathology; 2002 Feb 15; 40(2):133-42. PubMed ID: 11952857
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.